CN107921096A - 用于胰腺癌或结肠癌治疗的集落刺激因子 - Google Patents

用于胰腺癌或结肠癌治疗的集落刺激因子 Download PDF

Info

Publication number
CN107921096A
CN107921096A CN201680047956.4A CN201680047956A CN107921096A CN 107921096 A CN107921096 A CN 107921096A CN 201680047956 A CN201680047956 A CN 201680047956A CN 107921096 A CN107921096 A CN 107921096A
Authority
CN
China
Prior art keywords
csf
stimulating factor
colony stimulating
colony
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201680047956.4A
Other languages
English (en)
Chinese (zh)
Inventor
L·比韦罗·桑切斯
L·索布雷瓦尔斯·阿米耶瓦
R·米纳娜·普列托
J·森德拉·库达尔
J·克罗尔·萨斯特雷
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Endo Technology Co
Original Assignee
Endo Technology Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Endo Technology Co filed Critical Endo Technology Co
Publication of CN107921096A publication Critical patent/CN107921096A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN201680047956.4A 2015-07-30 2016-07-28 用于胰腺癌或结肠癌治疗的集落刺激因子 Pending CN107921096A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP15179043.3 2015-07-30
EP15179043 2015-07-30
PCT/EP2016/068007 WO2017017187A1 (en) 2015-07-30 2016-07-28 Colony stimulating factor for use in pancreatic or colon cancer treatment

Publications (1)

Publication Number Publication Date
CN107921096A true CN107921096A (zh) 2018-04-17

Family

ID=53765126

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201680047956.4A Pending CN107921096A (zh) 2015-07-30 2016-07-28 用于胰腺癌或结肠癌治疗的集落刺激因子

Country Status (6)

Country Link
US (1) US11020455B2 (enExample)
EP (1) EP3328415B1 (enExample)
JP (1) JP2018522030A (enExample)
CN (1) CN107921096A (enExample)
ES (1) ES2852002T3 (enExample)
WO (1) WO2017017187A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019206516A (ja) * 2018-05-23 2019-12-05 国立大学法人高知大学 膵癌細胞の浸潤転移抑制剤

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101790310A (zh) * 2007-03-15 2010-07-28 杰能斯有限公司 溶瘤痘苗病毒癌症治疗
CN102395379A (zh) * 2009-01-16 2012-03-28 特瓦制药工业有限公司 重组人白蛋白-人粒细胞集落刺激因子融合蛋白的新稳定制剂
CN103079586A (zh) * 2010-08-31 2013-05-01 健能隆医药技术（上海）有限公司 G-csf二聚体在治疗嗜中性粒细胞减少症中的应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3875859T2 (de) 1987-03-02 1993-05-13 Genetics Inst Zubereitungen zur verbesserung der adcc-therapien.
JPH05271095A (ja) * 1991-05-30 1993-10-19 Chugai Pharmaceut Co Ltd 抗癌剤
US20060008448A1 (en) * 1996-06-11 2006-01-12 Minzhen Xu Inhibition of li expression in mammalian cells
EP2275557A1 (en) * 2000-04-12 2011-01-19 Human Genome Sciences, Inc. Albumin fusion proteins
US9005613B2 (en) * 2003-06-16 2015-04-14 Immunomedics, Inc. Anti-mucin antibodies for early detection and treatment of pancreatic cancer
ATE493117T1 (de) 2007-04-05 2011-01-15 Sandoz Ag Stabile wässrige g-csf-formulierungen
US9132146B2 (en) 2009-12-23 2015-09-15 Gradalis, Inc. Furin-knockdown and GM-CSF-augmented (FANG) cancer vaccine

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101790310A (zh) * 2007-03-15 2010-07-28 杰能斯有限公司 溶瘤痘苗病毒癌症治疗
CN102395379A (zh) * 2009-01-16 2012-03-28 特瓦制药工业有限公司 重组人白蛋白-人粒细胞集落刺激因子融合蛋白的新稳定制剂
CN103079586A (zh) * 2010-08-31 2013-05-01 健能隆医药技术（上海）有限公司 G-csf二聚体在治疗嗜中性粒细胞减少症中的应用

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
A MIGUEL等: "Comparative antitumor effect among GM-CSF, IL-12 and GM-CSF+IL-12 genetically modified tumor cell vaccines", 《CANCER GENE THERAPY》 *
MERCE PIERA等: "Cytokines as adjuvants: effect on the immunogenicity of NeuAcα2-6GalNAc α-O-Ser/Thr (sialyl-Tn)", 《INTERNATIONAL JOURNAL OF CANCER》 *

Also Published As

Publication number Publication date
EP3328415B1 (en) 2020-11-25
WO2017017187A1 (en) 2017-02-02
US20180214517A1 (en) 2018-08-02
EP3328415A1 (en) 2018-06-06
US11020455B2 (en) 2021-06-01
JP2018522030A (ja) 2018-08-09
ES2852002T3 (es) 2021-09-10

Similar Documents

Publication Publication Date Title
Qiu et al. Clinical application of cytokines in cancer immunotherapy
Mollica Poeta et al. Chemokines and chemokine receptors: new targets for cancer immunotherapy
Berraondo et al. Cytokines in clinical cancer immunotherapy
Jarosz-Biej et al. M1-like macrophages change tumor blood vessels and microenvironment in murine melanoma
Lurje et al. In situ vaccination as a strategy to modulate the immune microenvironment of hepatocellular carcinoma
Vacchelli et al. Trial watch: immunostimulatory cytokines
JP2005029561A (ja) コンセンサスヒト白血球インターフェロンを含有する抗腫瘍剤
US20220380427A1 (en) Dual cytokine fusion proteins comprising il-10
JP7762570B2 (ja) 癌又は感染性疾患を処置するためのＩＬ－２／ＩＬ－１５Ｒβγアゴニスト投薬レジメン
US20230287075A1 (en) Dual cytokine fusion proteins comprising multi-subunit cytokines
Ma et al. IL‐24 protects against Salmonella typhimurium infection by stimulating early neutrophil Th1 cytokine production, which in turn activates CD8+ T cells
Cao et al. L-arginine and docetaxel synergistically enhance anti-tumor immunity by modifying the immune status of tumor-bearing mice
van Elsas et al. Host genetics and tumor environment determine the functional impact of neutrophils in mouse tumor models
CN107206053B (zh) 用于治疗血细胞减少症或减少血细胞减少症的持续时间的佛波醇酯组合物和方法
Li et al. Local administration of mRNA encoding cytokine cocktail confers potent anti-tumor immunity
Rubinstein et al. G-CSF/anti-G-CSF antibody complexes drive the potent recovery and expansion of CD11b+ Gr-1+ myeloid cells without compromising CD8+ T cell immune responses
US20250032582A1 (en) Compositions and methods for cancer immunotherapy
US20210188933A1 (en) Methods of treating pancytopenia
Wang et al. Interleukin-15 suppresses gastric cancer liver metastases by enhancing natural killer cell activity in a murine model
CN107921096A (zh) 用于胰腺癌或结肠癌治疗的集落刺激因子
Sagara et al. The efficacy and safety of FSK0808, filgrastim biosimilar: a multicenter, non-randomized study in Japanese patients with breast cancer
JP2023505303A (ja) 癌治療におけるｉｌ－１５及びｃｄ４０アゴニストの組合せ免疫療法
Xu et al. Recombinant human thrombopoietin combined with interleukin-2 improves the effects of chemosensitivity and thrombocytopenia on a basic gemcitabine and carboplatin combination therapy for non-small cell lung cancer in a nude mouse model
CN104127871A (zh) Cxcl4单抗治疗肿瘤及化疗后肿瘤加速再增殖基因筛选法
Sim et al. Enhanced Antitumor Immune Response in 2′‐5′ Oligoadenylate Synthetase‐Like 1‐(OASL1‐) Deficient Mice upon Cisplatin Chemotherapy and Radiotherapy

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20180417